Zheng Quan Ri Bao·2026-01-06 13:12Core Viewpoint - The company, CanSino, has successfully positioned its product, Manhaixin®, as the only approved quadrivalent meningococcal conjugate vaccine in China, targeting the mid-to-high-end infant vaccine market, with increasing market acceptance and sales growth indicating a strong demand for high-quality vaccines in the domestic market [1] Group 1: Product Development and Market Expansion - Manhaixin® has seen steady sales growth, confirming the domestic market's demand for premium infant vaccines [1] - The company has submitted a supplementary application to expand the age indication of Manhaixin® to children aged 3 months to 6 years and plans to pursue further age expansion for adolescents and adults (ages 7 to 59) [1] - Manhaixin® was launched in Indonesia in September 2025, marking the start of its sales in the local market, with ongoing efforts to expand into other target countries and regions [1] Group 2: Financial Performance - For the third quarter of 2025, the company reported revenue of approximately 693 million yuan, representing a year-on-year increase of 22% [1] - The sales revenue from meningococcal products for the first three quarters reached approximately 662 million yuan, a 28% increase compared to the same period last year [1] Group 3: Incentives and Growth Targets - The company has announced a new equity incentive plan, setting revenue growth targets for 2025, indicating a commitment to achieving these objectives [1]